Assertio Holdings, Inc. (ASRT)

$1.05

+0.01

(+0.96%)

Market is closed - opens 7 PM, 17 Jun 2024

Insights on Assertio Holdings, Inc.

  • Decreasing Revenue

    Revenue is down for the last 6 quarters, 50.35M → 32.44M (in $), with an average decrease of 8.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -279.54M → -4.51M (in $), with an average increase of 779.8% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 39.9% return, outperforming this stock by 122.8%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 38.4% return, outperforming this stock by 77.7%

Performance

  • $1.01
    $1.05
    $1.05
    downward going graph

    3.81%

    Downside

    Day's Volatility :3.81%

    Upside

    0.0%

    downward going graph
  • $0.73
    $6.41
    $1.05
    downward going graph

    30.25%

    Downside

    52 Weeks Volatility :88.57%

    Upside

    83.62%

    downward going graph

Returns

PeriodAssertio Holdings, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
0.96%
0.4%
0.0%
6 Months
0.0%
8.7%
0.0%
1 Year
-82.44%
10.3%
0.0%
3 Years
-38.95%
17.0%
-23.8%

Highlights

Market Capitalization
98.9M
Book Value
$1.41
Earnings Per Share (EPS)
-4.65
PEG Ratio
1.2
Wall Street Target Price
2.92
Profit Margin
-234.4%
Operating Margin TTM
-11.15%
Return On Assets TTM
1.35%
Return On Equity TTM
-172.9%
Revenue TTM
142.1M
Revenue Per Share TTM
1.73
Quarterly Revenue Growth YOY
-23.599999999999998%
Gross Profit TTM
138.3M
EBITDA
35.0M
Diluted Eps TTM
-4.65
Quarterly Earnings Growth YOY
-0.19
EPS Estimate Current Year
-0.16
EPS Estimate Next Year
-0.03
EPS Estimate Current Quarter
-0.03
EPS Estimate Next Quarter
-0.02

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Assertio Holdings, Inc.(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 178.1%

Current $1.05
Target $2.92

Company Financials

FY18Y/Y Change
Revenue
311.8M
↓ 18.11%
Net Income
36.9M
↓ 136.01%
Net Profit Margin
11.84%
↑ 38.76%
FY19Y/Y Change
Revenue
229.5M
↓ 26.39%
Net Income
-217.2M
↓ 688.49%
Net Profit Margin
-94.64%
↓ 106.48%
FY20Y/Y Change
Revenue
106.3M
↓ 53.69%
Net Income
-28.1M
↓ 87.04%
Net Profit Margin
-26.48%
↑ 68.16%
FY21Y/Y Change
Revenue
111.0M
↑ 4.46%
Net Income
-1.3M
↓ 95.45%
Net Profit Margin
-1.15%
↑ 25.33%
FY22Y/Y Change
Revenue
156.2M
↑ 40.73%
Net Income
109.6M
↓ 8657.77%
Net Profit Margin
70.17%
↑ 71.32%
FY23Y/Y Change
Revenue
152.1M
↓ 2.67%
Net Income
-331.9M
↓ 402.8%
Net Profit Margin
-218.28%
↓ 288.45%
Q4 FY22Q/Q Change
Revenue
50.4M
↑ 47.18%
Net Income
88.6M
↑ 2021.54%
Net Profit Margin
175.86%
↑ 163.66%
Q1 FY23Q/Q Change
Revenue
42.5M
↓ 15.66%
Net Income
-3.5M
↓ 103.93%
Net Profit Margin
-8.2%
↓ 184.06%
Q2 FY23Q/Q Change
Revenue
41.0M
↓ 3.47%
Net Income
8.5M
↓ 343.11%
Net Profit Margin
20.66%
↑ 28.86%
Q3 FY23Q/Q Change
Revenue
35.6M
↓ 13.09%
Net Income
-279.5M
↓ 3400.4%
Net Profit Margin
-784.64%
↓ 805.3%
Q4 FY23Q/Q Change
Revenue
33.0M
↓ 7.42%
Net Income
-57.4M
↓ 79.47%
Net Profit Margin
-173.97%
↑ 610.67%
Q1 FY24Q/Q Change
Revenue
32.4M
↓ 1.63%
Net Income
-4.5M
↓ 92.14%
Net Profit Margin
-13.9%
↑ 160.07%
FY18Y/Y Change
Total Assets
932.9M
↓ 10.18%
Total Liabilities
712.5M
↓ 18.02%
FY19Y/Y Change
Total Assets
527.2M
↓ 43.49%
Total Liabilities
469.2M
↓ 34.15%
FY20Y/Y Change
Total Assets
303.3M
↓ 42.47%
Total Liabilities
247.8M
↓ 47.2%
FY21Y/Y Change
Total Assets
326.5M
↑ 7.67%
Total Liabilities
224.1M
↓ 9.54%
FY22Y/Y Change
Total Assets
413.9M
↑ 26.75%
Total Liabilities
188.2M
↓ 16.04%
FY23Y/Y Change
Total Assets
286.4M
↓ 30.8%
Total Liabilities
148.4M
↓ 21.13%
Q4 FY22Q/Q Change
Total Assets
413.9M
↑ 28.01%
Total Liabilities
188.2M
↓ 0.13%
Q1 FY23Q/Q Change
Total Assets
414.3M
↑ 0.09%
Total Liabilities
163.6M
↓ 13.06%
Q2 FY23Q/Q Change
Total Assets
405.2M
↓ 2.2%
Total Liabilities
150.9M
↓ 7.76%
Q3 FY23Q/Q Change
Total Assets
380.0M
↓ 6.21%
Total Liabilities
187.2M
↑ 24.02%
Q4 FY23Q/Q Change
Total Assets
286.4M
↓ 24.63%
Total Liabilities
148.4M
↓ 20.7%
Q1 FY24Q/Q Change
Total Assets
282.0M
↓ 1.56%
Total Liabilities
147.5M
↓ 0.64%
FY18Y/Y Change
Operating Cash Flow
72.5M
↑ 16.62%
Investing Cash Flow
-7.1M
↓ 112.23%
Financing Cash Flow
-81.4M
↓ 26.64%
FY19Y/Y Change
Operating Cash Flow
90.5M
↑ 24.8%
Investing Cash Flow
-1.5M
↓ 79.09%
Financing Cash Flow
-157.8M
↑ 94.02%
FY20Y/Y Change
Operating Cash Flow
-65.6M
↓ 172.48%
Investing Cash Flow
512.8M
↓ 34725.32%
Financing Cash Flow
-468.6M
↑ 196.86%
FY21Y/Y Change
Operating Cash Flow
5.5M
↓ 108.42%
Investing Cash Flow
-18.5M
↓ 103.61%
Financing Cash Flow
29.0M
↓ 106.19%
FY22Y/Y Change
Operating Cash Flow
78.6M
↑ 1323.1%
Investing Cash Flow
-42.7M
↑ 130.35%
Financing Cash Flow
-7.8M
↓ 126.85%
Q4 FY22Q/Q Change
Operating Cash Flow
26.7M
↑ 165.77%
Investing Cash Flow
-25.8M
↑ 6849.87%
Financing Cash Flow
-798.0K
↓ 127.63%
Q1 FY23Q/Q Change
Operating Cash Flow
22.7M
↓ 14.91%
Investing Cash Flow
-703.0K
↓ 97.27%
Financing Cash Flow
-19.0M
↑ 2274.69%
Q2 FY23Q/Q Change
Operating Cash Flow
18.6M
↓ 18.12%
Investing Cash Flow
-703.0K
↑ 0.0%
Financing Cash Flow
-16.3M
↓ 13.85%

Technicals Summary

Sell

Neutral

Buy

Assertio Holdings, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Assertio Holdings, Inc.
Assertio Holdings, Inc.
2.94%
0.0%
-82.44%
-38.95%
-91.25%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-4.55%
12.95%
38.78%
37.39%
57.46%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
0.24%
3.33%
-0.36%
13.23%
13.23%
Zoetis Inc.
Zoetis Inc.
-1.82%
-13.3%
-0.11%
-7.37%
53.91%
Viatris Inc.
Viatris Inc.
-7.71%
0.69%
-1.17%
-33.18%
-37.76%
Catalent, Inc.
Catalent, Inc.
0.42%
32.44%
25.78%
-48.53%
9.71%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Assertio Holdings, Inc.
Assertio Holdings, Inc.
1.2
NA
1.2
-0.16
-1.73
0.01
NA
1.41
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
37.03
37.03
0.44
4.07
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.27
28.27
1.69
0.46
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
33.01
33.01
2.58
5.76
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
NA
2.74
0.0
0.03
0.05
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.24
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Assertio Holdings, Inc.
Assertio Holdings, Inc.
Buy
$98.9M
-91.25%
1.2
-234.4%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.7B
57.46%
37.03
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.7B
13.23%
28.27
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$78.2B
53.91%
33.01
27.38%
Viatris Inc.
Viatris Inc.
Hold
$12.1B
-37.76%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
9.71%
211.02
-28.44%

Institutional Holdings

  • Nantahala Capital Management, LLC

    9.75%
  • BlackRock Inc

    6.68%
  • Vanguard Group Inc

    5.17%
  • AQR Capital Management LLC

    3.40%
  • Renaissance Technologies Corp

    2.20%
  • Geode Capital Management, LLC

    2.15%

Company Information

assertio reflects an aspirational mindset that is forward thinking, energetic, and entrepreneurial in spirit. ticker symbol: asrt

Organization
Assertio Holdings, Inc.
Employees
53
CEO
Ms. Heather L. Mason
Industry
Health Technology

FAQs